Frontlight ResearchEarly access
Myasthenia gravis trials in United States
32 of 52 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Altamonte Springs, Boca Raton, Burlington, Centerville, Chapel Hill, Charleston, Chattanooga, Cincinnati, Dallas, El Paso, Falls Church, Farmington, Greenfield, Jacksonville, Kansas City, Longmont, Maitland, McAllen, McKinney, Phoenix, Tampa, Washington D.C., Winston-Salem
- Age
- 18 years and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - Phase 1Taking peopleStudy of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
- Where
- Newport Beach, New York, Palo Alto, Salt Lake City, Seattle
- Age
- 18 years to 75 years
- People
- 57 worldwide
- Run by
- Kite, A Gilead Company
See details and how to joinNCT07304154 - Phase 2Taking peopleADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Where
- Amherst, Austin, Carlsbad, Chattanooga, Las Vegas, Miami, Tampa
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00 - Phase 3Taking peopleStudy to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Where
- Atlanta, Augusta, Carlsbad, Chapel Hill, Charleston, Charlottesville, Cincinnati, Clearwater, Dallas, Denton, Denver, Detroit, Durham, East Lansing, Eugene, Fort Collins, Foxborough, Greenfield, Houston, Huntsville, Irvine, Lexington, Los Angeles, Lubbock, Memphis, Miami, Mobile, New Haven, New Orleans, New York, Nicholasville, Oklahoma City, Omaha, Ormond Beach, Phoenix, Port Charlotte, Raleigh, Rancho Mirage, Richmond, Rockledge, San Francisco, Schaumburg, Scottsdale, Tampa, Totowa, Tucson, Washington D.C., Yukon
- Age
- 18 years to 80 years
- People
- 231 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Amherst, Cincinnati, Columbus, Greenfield, O'Fallon, Scottsdale
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00 - Phase 3Taking peopleA Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Columbus, Scottsdale
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00 - Phase 3Taking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Augusta, Aurora, Boca Raton, Boston, Burlington, Charleston, Cincinnati, Cleveland, Columbus, Cordova, Dallas, Durham, Jacksonville, Kansas City, Los Angeles, New Haven, Palo Alto, Paradise Valley, Pasadena, Port Charlotte, Scottsdale, St Louis, Tampa
- Age
- 18 years and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - Phase 2/3WithdrawnA Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
- Where
- Chicago, Denton
- Age
- 12 years to 17 years
- People
- 8 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06055959 · EU 2022-502072-23-00 - Phase 2/3Taking peopleA Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Where
- Ann Arbor, Aurora, Hershey, Lawrence, Los Angeles, Palo Alto, Philadelphia, Phoenix, Pittsburgh, San Francisco, Tampa
- Age
- 2 years to 17 years
- People
- 12 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05265273 · EU 2022-502539-21-00 - Phase 2/3Enrolling by invitationEvaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Where
- Charlotte, Charlottesville, Chicago
- Age
- 2 years to 18 years
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00 - Phase 3Taking peopleComparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Where
- Austin, Boca Raton, Colorado Springs, Cordova, Dallas, Detroit, East Lansing, Farmington, Fort Collins, Foxborough, Fullerton, Houston, Indianapolis, Kirkland, New Orleans, New York, O'Fallon, Pomona, Raleigh, Winston-Salem
- Age
- 18 years to 74 years
- People
- 115 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07217587 · EU 2025-521130-28-00 - Phase 3Taking peopleA Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Where
- Boca Raton, Fayetteville, Houston, Pasadena
- Age
- 18 years to 80 years
- People
- 195 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00 - Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- Where
- Clearwater, Colorado Springs, Farmington Hills, Greenville, Maitland, New Bern
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- TG Therapeutics, Inc.
See details and how to joinNCT07673744 · EU 2025-524630-26-00 - Phase 1Taking peopleA Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- Where
- Ann Arbor, Cleveland, Columbus, La Jolla, Milwaukee, New York, Omaha, Rochester
- Age
- 18 years and over
- People
- 100
- Run by
- TG Therapeutics, Inc.
See details and how to joinNCT06680037 - Phase 2Taking peopleA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
- Where
- Austin, Chicago, Philadelphia, Seattle
- Age
- 2 years to 17 years
- People
- 15 worldwide
- Run by
- Amgen
See details and how to joinNCT06987539 · EU 2025-520993-20-00 - Phase 1Taking peopleStudy of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
- Where
- Columbus, Dallas, Detroit, Houston, Los Angeles, Minneapolis, New York, Orange, Palo Alto, Philadelphia, Portland, Rochester, Tampa
- Age
- 18 years and over
- People
- 30
- Run by
- Kite, A Gilead Company
See details and how to joinNCT06626919 - Phase 1/2Taking peopleRESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Where
- Aurora, Boston, Chicago, Houston, Jacksonville, Kansas City, New York, Orange, Portland, Rochester, Sacramento, San Francisco, Seattle, Worcester
- Age
- 18 years to 70 years
- People
- 24
- Run by
- Cabaletta Bio
See details and how to joinNCT06359041 - Phase 2/3Active, not recruitingA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
- Where
- Charlotte, Charlottesville, Denton
- Age
- 2 years to 17 years
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00 - Phase 2Taking peopleADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Where
- Amherst, Austin, Boston, Carlsbad, Chapel Hill, Chattanooga, Cincinnati, Columbus, Detroit, Durham, Las Vegas, Miami, San Antonio, Tampa
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00 - Phase 3Taking peopleZilucoplan for Severe gMG Exacerbations
- Where
- Columbus, Kansas City, Tampa
- Age
- 18 years and over
- People
- 15
- Run by
- Miriam Freimer
See details and how to joinNCT07215949 - Phase 2Taking peopleSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- Where
- Augusta, Aurora, Boca Raton, Carlsbad, Chapel Hill, Columbia, Columbus, Irvine, Memphis, Portland, Tampa
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- NMD Pharma A/S
See details and how to joinNCT06414954 - Phase 1/2Taking peopleStudy of Aritinercept in Patients With Generalized Myasthenia Gravis
- Where
- Altamonte Springs, Boca Raton, Chicago, Dearborn, Flint, Homestead, Houston, Miami, O'Fallon, Pasadena
- Age
- 18 years to 85 years
- People
- 81
- Run by
- Aurinia Pharmaceuticals Inc.
See details and how to joinNCT07596901 - Phase 2/3Taking peopleKYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Where
- Columbia, Houston, Indianapolis, Los Angeles, Miami, Murray, Orange, Palo Alto, Philadelphia, Portland
- Age
- 18 years to 75 years
- People
- 66 worldwide
- Run by
- Kyverna Therapeutics
See details and how to joinNCT06193889 · EU 2023-509892-17-00 - Phase 1/2Taking peopleDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
- Where
- Cincinnati, St Louis, Washington D.C.
- Age
- 12 years and over
- People
- 50
- Run by
- Cartesian Therapeutics
See details and how to joinNCT07089121 - Phase 4Taking peopleA Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
- Where
- Chicago, Knoxville, Neptune City, Raleigh, Schaumburg
- Age
- 18 years and over
- People
- 75 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07221838 · EU 2025-522555-26-00